Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review

Global Markets Direct’s, ‘Lee's Pharmaceutical Holdings Limited – Product Pipeline Review – 2016’, provides an overview of the Lee's Pharmaceutical Holdings Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lee's Pharmaceutical Holdings Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Lee's Pharmaceutical Holdings Limited

The report provides overview of Lee's Pharmaceutical Holdings Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Lee's Pharmaceutical Holdings Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Lee's Pharmaceutical Holdings Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Lee's Pharmaceutical Holdings Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lee's Pharmaceutical Holdings Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lee's Pharmaceutical Holdings Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Lee's Pharmaceutical Holdings Limited Snapshot 7

Lee's Pharmaceutical Holdings Limited Overview 7

Key Facts 7

Lee's Pharmaceutical Holdings Limited - Research and Development Overview 8

Key Therapeutic Areas 8

Lee's Pharmaceutical Holdings Limited - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance 16

Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Lee's Pharmaceutical Holdings Limited - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products 20

IND/CTA Filed Products/Combination Treatment Modalities 20

Preclinical Products/Combination Treatment Modalities 21

Lee's Pharmaceutical Holdings Limited - Drug Profiles 22

(adapalene + clindamycin hydrochloride) - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

AK-12 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

azilsartan - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

gimatecan - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

istaroxime - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

levobetaxolol hydrochloride - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

levocarnitine propionate hydrochloride - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LQ-7 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

pazufloxacin - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

procarbazine hydrochloride - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

RGN-259 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

rostafuroxin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

STIA-1014 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

tecarfarin sodium - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

trazodone hydrochloride - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ZK-001 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ZK-002 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

ZK-003 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

ZK-004 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ZK-009 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ZK-010 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ZK-011 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ZK-012 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ZK-013 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

ZK-014 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ZK-015 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ZK-016 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Lee's Pharmaceutical Holdings Limited - Pipeline Analysis 61

Lee's Pharmaceutical Holdings Limited - Pipeline Products by Target 61

Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 63

Lee's Pharmaceutical Holdings Limited - Pipeline Products by Molecule Type 64

Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action 65

Lee's Pharmaceutical Holdings Limited - Dormant Projects 67

Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products 68

Discontinued Pipeline Product Profiles 68

betrixaban 68

ecallantide 68

gimatecan 68

NOV-002 69

NOV-205 69

prulifloxacin 69

RGN-259 69

Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries 70

Head Office 70

Other Locations & Subsidiaries 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

List of Tables

Lee's Pharmaceutical Holdings Limited, Key Facts 7

Lee's Pharmaceutical Holdings Limited – Pipeline by Indication, 2016 9

Lee's Pharmaceutical Holdings Limited – Pipeline by Stage of Development, 2016 11

Lee's Pharmaceutical Holdings Limited – Monotherapy Products in Pipeline, 2016 12

Lee's Pharmaceutical Holdings Limited – Combination Treatment Modalities in Pipeline, 2016 13

Lee's Pharmaceutical Holdings Limited – Partnered Products in Pipeline, 2016 14

Lee's Pharmaceutical Holdings Limited – Partnered Products/ Combination Treatment Modalities, 2016 15

Lee's Pharmaceutical Holdings Limited – Pre-Registration, 2016 16

Lee's Pharmaceutical Holdings Limited – Phase III, 2016 17

Lee's Pharmaceutical Holdings Limited – Phase II, 2016 18

Lee's Pharmaceutical Holdings Limited – Phase I, 2016 19

Lee's Pharmaceutical Holdings Limited – IND/CTA Filed, 2016 20

Lee's Pharmaceutical Holdings Limited – Preclinical, 2016 21

Lee's Pharmaceutical Holdings Limited – Pipeline by Target, 2016 62

Lee's Pharmaceutical Holdings Limited – Pipeline by Route of Administration, 2016 63

Lee's Pharmaceutical Holdings Limited – Pipeline by Molecule Type, 2016 64

Lee's Pharmaceutical Holdings Limited – Pipeline Products by Mechanism of Action, 2016 66

Lee's Pharmaceutical Holdings Limited – Dormant Developmental Projects,2016 67

Lee's Pharmaceutical Holdings Limited – Discontinued Pipeline Products, 2016 68

Lee's Pharmaceutical Holdings Limited, Subsidiaries 70

List of Figures

List of Figures

Lee's Pharmaceutical Holdings Limited – Pipeline by Top 10 Indication, 2016 9

Lee's Pharmaceutical Holdings Limited – Pipeline by Stage of Development, 2016 11

Lee's Pharmaceutical Holdings Limited – Monotherapy Products in Pipeline, 2016 12

Lee's Pharmaceutical Holdings Limited – Partnered Products in Pipeline, 2016 14

Lee's Pharmaceutical Holdings Limited – Pipeline by Top 10 Target, 2016 61

Lee's Pharmaceutical Holdings Limited – Pipeline by Route of Administration, 2016 63

Lee's Pharmaceutical Holdings Limited – Pipeline by Molecule Type, 2016 64

Lee's Pharmaceutical Holdings Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 65

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports